Reduce Transfusion Budget

In recent decades, the transfusion of apheresis platelets has been viewed as a blood safety strategy to limit donor exposure for patients. However, in most cases the purchase price of apheresis platelets for hospitals is much higher than the price of pooled whole-blood-derived platelets.

When pooled whole-blood-derived platelets undergo pathogen inactivation with the INTERCEPT™ Blood System, the risk of increased donor exposure is reduced. As studies on the therapeutic equivalence for both types of platelet concentrates have shown, pathogen inactivation allows you to transfuse a higher percentage of less-expensive whole-blood-derived platelets, and to limit the transfusion of apheresis platelets to patients who require HLA/HPA-typed platelets.  

Depending on the current ratio of apheresis versus whole-blood-derived platelets, this can represent a significant reduction in your hospital’s platelet transfusion budget.